Joint radionuclide therapy-immunotherapy approach effective in prostate cancer model

(Society of Nuclear Medicine and Molecular Imaging) A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine. The results of the murine study indicate that radionuclide therapy promotes prostate cancer immunogenicity, provoking a cellular response that makes the tumors more receptive to immunotherapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news